Oral Contraceptives

Do not use hormonal contraceptives with mifepristone.

Mitotane decreases the levels and efficacy of hormonal contraceptives. Avoid concomitant use.

Concomitant use may increase thrombotic risk associated with combined hormonal contraceptives due to tranexamic acid's antifibrinolytic properties.

Acitretin interferes with the contraceptive effect of microdosed progestin preparations. These preparations are not recommended for use with acitretin.

Decreased hormonal exposure during and for 28 days after aprepitant. Use alternative contraception methods during treatment and for 1 month after.

Coadministration may lead to contraceptive failure or increase in breakthrough bleeding.

Bexarotene may reduce plasma concentrations of oral or systemic hormonal contraceptives. Non-hormonal contraception is strongly recommended for females with reproductive potential.

Decreased efficacy possibly resulting in pregnancy and breakthrough bleeding; use a different or additional form of contraception.

Bosentan reduces effectiveness of oral, injectable, transdermal, and implantable hormonal contraceptives by decreasing exposure to ethinyl estradiol (31% average, up to 66%) and norethindrone (14% average, up to 56%).

May decrease hepatic metabolism of dexamethasone and increase exposures, which may increase the risk of adverse reactions.

Co-administration of enasidenib may decrease concentrations of hormonal contraceptives. Consider alternative methods of contraception.

Decreased hormonal exposure during and for 28 days after administration. Use alternative or back-up contraception methods.

Decreased hormonal exposure during administration and for 28 days after last dose. Effective alternative or back-up contraception methods recommended.

Coadministration associated with 55% decrease in lorazepam half-life and 50% increase in volume of distribution, resulting in 3.7-fold increase in plasma concentrations.

May reduce effectiveness of oral contraceptives; additional barrier contraceptive methods must be used.

Omaveloxolone weakly induces CYP3A4, which may reduce the efficacy of hormonal contraceptives. Avoid concomitant use with combined hormonal contraceptives, implants, and progestin-only pills.

Repotrectinib decreases progestin or estrogen exposure, reducing contraceptive effectiveness. Avoid concomitant use; use nonhormonal contraception instead.

Rifapentine may reduce the effectiveness of hormonal contraceptives. Alternative non-hormonal or barrier methods recommended during treatment.

Concomitant use is not recommended. If clinically necessary, initiate tizanidine with 2 mg dose and titrate in 2-4 mg steps daily.

Moderate CYP1A2 inhibitor; concomitant use not recommended due to risk of hypotension, bradycardia, or excessive drowsiness.

Decreased contraceptive efficacy and increased breakthrough bleeding, especially at doses greater than 200 mg/day. Ethinyl estradiol exposure decreased 18-30% at topiramate doses of 200-800 mg/day.

Tovorafenib may decrease progestin and ethinyl estradiol exposure, leading to contraceptive failure and breakthrough bleeding. Avoid coadministration or use additional nonhormonal contraception.

Concomitant use may decrease hormonal contraceptive concentrations, leading to contraception failure and breakthrough bleeding.

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring.

Oral contraceptives produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

May produce hyperglycemia and lead to loss of glycemic control.

Increased alprazolam maximum plasma concentration by 18%, decreased clearance by 22%, and increased half-life by 29%.

Coadministration increased alprazolam maximum plasma concentration by 18%, decreased clearance by 22%, and increased half-life by 29%.

May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive.

Amoxicillin may reduce efficacy of combined oral estrogen/progesterone contraceptives by affecting intestinal flora and lowering estrogen reabsorption.

May reduce efficacy of combined oral estrogen/progesterone contraceptives by affecting intestinal flora and lowering estrogen reabsorption.

Amoxicillin may affect gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

May be less effective with increased breakthrough bleeding may occur.

Effectiveness of steroidal contraceptives may be reduced when used with armodafinil via CYP3A4/5 induction. Alternative or concomitant contraception methods recommended.

Effectiveness of hormonal contraceptives may be reduced by artemether and lumefantrine. Use an additional method of birth control.

May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive.

May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive.

Oral contraceptives may decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Cefuroxime may affect gut flora, leading to lower estrogen reabsorption and reduced efficacy of oral contraceptives.

Cefuroxime axetil may affect gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

XCOPRI decreases oral contraceptive effectiveness; women should use additional or alternative non-hormonal birth control.

Increases biliary cholesterol secretion and may counteract the effectiveness of chenodiol.

Effectiveness may be diminished as clobazam is a weak CYP3A4 inducer and some hormonal contraceptives are metabolized by CYP3A4.

Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reduction if necessary.

Increase cyclosporine concentrations. Dosage adjustment essential.

Coadministration with dabrafenib can result in decreased concentrations and loss of efficacy. Substitute or monitor for loss of efficacy if unavoidable.

Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.

Deferasirox may induce CYP3A4 resulting in decreased hormonal contraceptive concentration. Monitor for reduced effectiveness.

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Oral contraceptives may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Concurrent use of tetracycline may render oral contraceptives less effective.

Concurrent use of tetracycline may render oral contraceptives less effective.

ELAFIBRANOR is a weak CYP3A4 inducer that may reduce systemic exposure of progestin and ethinyl estradiol, potentially leading to contraceptive failure and breakthrough bleeding.

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.

Weak CYP3A4 inhibitor; concomitant use of multiple weak inhibitors may increase risk of adverse reactions.

Oral contraceptives increase folate turnover and urinary loss.

Oral contraceptives may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Oral contraceptives may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Oral contraceptives may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.

Oral contraceptives tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.

Griseofulvin may enhance metabolism of the estrogen component, reducing contraceptive effectiveness and causing menstrual irregularities.

Oral contraceptives may decrease hepatic metabolism of corticosteroids, increasing their effect.

Oral contraceptives may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required. Should be taken at least 1 hour prior to or 11 hours after SOLIQUA administration.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Ivosidenib may decrease hormonal contraceptive concentrations, reducing efficacy. Consider alternative methods of contraception.

Estrogens in oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Estrogen-containing oral contraceptives increase serum thyroxine-binding globulin, potentially decreasing free levothyroxine. Patients without functioning thyroid may require increased thyroid dose.

Oral contraceptives may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Estrogen-containing oral contraceptives increase thyroxine-binding globulin, potentially decreasing free levothyroxine. Patients without functioning thyroid gland may need increased thyroid dose.

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Effectiveness may be reduced due to metabolism via CYP3A and PXR-regulated enzymes. Effective alternative non-hormonal forms of contraception or additional contraceptive methods are recommended.

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

May decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

May decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Metreleptin may alter CYP450 enzyme formation, potentially affecting oral contraceptive metabolism. Therapeutic monitoring recommended upon initiation or discontinuation.

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Drug interaction study conducted; no dose adjustment recommended when coadministered with mirabegron.

Effectiveness of steroidal contraceptives may be reduced when used with modafinil. Alternative or concomitant contraception methods recommended during treatment and for one month after discontinuation.

Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended.

Mycophenolate Mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended.

Moderate CYP3A4 inhibitor that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary.

Oxcarbazepine may decrease the effectiveness of hormonal contraceptives, including oral and implant formulations.

Penicillin G benzathine may impair the efficacy of oral contraceptives, potentially resulting in unwanted pregnancy. Alternative contraception methods should be considered.

SYMLIN may delay absorption of oral contraceptives. Administer at least 1 hour prior to or 2 hours after SYMLIN injection.

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Estrogens in contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Serum folate levels may be depressed by oral contraceptive therapy.

CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Rufinamide may reduce effectiveness of hormonal contraceptives; additional non-hormonal contraception recommended.

Exercise caution with oral contraceptives as CYP3A4 substrate where decrease in effectiveness is undesirable.

SILTUXIMAB may increase metabolism of oral contraceptives via CYP3A4, potentially decreasing effectiveness. Exercise caution and monitor effectiveness.

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

Chronically administered oral contraceptives may enhance neuromuscular blocking effect by reducing plasma cholinesterase activity.

Chronically administered oral contraceptives may enhance neuromuscular blocking effect by reducing plasma cholinesterase activity.

Sugammadex may bind to progestogen, decreasing exposure and efficacy. Patients must use additional non-hormonal contraception for 7 days after administration.

Concurrent use of tetracycline may render oral contraceptives less effective.

Hormonal contraceptives increase thromboembolism risk; unclear if concomitant use with thalidomide further increases this risk.

Estrogen-containing oral contraceptives increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid glands may need increased thyroid doses.

Estrogen-containing formulations increase serum thyroxine-binding globulin (TBg), decreasing free levothyroxine (T4) in patients without functioning thyroid glands. May require increased thyroid dose.

Concurrent use of tigecycline with oral contraceptives may render oral contraceptives less effective.

MOUNJARO delays gastric emptying and may reduce contraceptive efficacy; switch to non-oral method or add barrier contraception for 4 weeks after initiation and dose escalations.

Concomitant use not recommended; if necessary, monitor for hypotension, bradycardia, or excessive drowsiness and reduce or discontinue tizanidine.

Exercise caution with tocilizumab coadministration as CYP3A4 inhibition may decrease oral contraceptive effectiveness.

Exercise caution when coadministering tocilizumab as it may decrease oral contraceptive effectiveness via CYP3A4 induction.

Oral contraceptive estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.

Coadministration increased maximum plasma concentration by 6%, decreased clearance by 32%, and increased half-life by 16%.

May impair the ability of ulipristal acetate to delay ovulation; timing of initiation and barrier method use recommended.

Increase hepatic cholesterol secretion and may counteract the effectiveness of ursodiol.

Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol effectiveness.

Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol effectiveness.

Levetiracetam did not influence pharmacokinetics of oral contraceptive containing ethinyl estradiol and levonorgestrel or hormone levels; oral contraceptive did not affect levetiracetam pharmacokinetics.

No dose adjustment needed when co-administered with montelukast sodium.

No dose adjustment needed when co-administered with montelukast sodium.